The side effects of the prostaglandin analogues

Holló, Gábor

doi:10.1517/14740338.6.1.45

Cited by 145 publications

(98 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 Travoprost is a synthetic prostaglandin F2a analogue that exerts its IOP-lowering effect through the prostaglandin FP receptors situated at the ciliary muscle 8 and the trabecular meshwork. 9 Travoprost is increasingly becoming a popular first-line monotherapy option for POAG patients 10 as there is cumulative evidence suggesting good quality of shortterm 24-hour IOP control with low fluctuation, especially with evening administration.…”

mentioning

confidence: 99%

Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma

Riva

Katsanos

Floriani

et al. 2014

Journal of Glaucoma

View full text Add to dashboard Cite

Purpose: The aim of the study was to evaluate the long-term 24-hour intraocular pressure (IOP) efficacy of travoprost monotherapy in primary open-angle glaucoma patients.Patients and Methods: A total of 36 previously untreated primary open-angle glaucoma patients were enrolled in this 5-year study.Patients underwent an untreated 24-hour IOP evaluation. Subsequently all patients were assigned to topical therapy with travoprost 0.004% eye-drops preserved with benzalkonium chloride (Travatan, Alcon Laboratories Inc., Fort Worth, TX) administered once in the evening (8:00 PM) in both eyes. All patients were then scheduled for a 24-hour IOP assessment approximately 12 months after the baseline visit. This schedule of follow-up was maintained for the whole duration of the trial. The predetermined range of target IOP reduction selected in this cohort of patients ranged between 20% and 30%.Results: A total of 34 patients completed all phases of the investigation. The mean survival time was 57.3 ± 2.0 months and the cumulative survival rate was 0.82 ± 0.6 at 60 months. Travoprost reduced the mean 24-hour IOP from 23.4 ± 1.7 mm Hg at baseline to 16.8 ± 2.4 mm Hg (28.4%), 16.8 ± 2.5 mm Hg (28.1%), 16.8 ± 2.4 mm Hg (28.5%), 16.7 ± 2.5 mm Hg (28.6%), and 16.9 ± 2.4 mm Hg (27.8%), respectively at the end of the first, second, third, fourth, and fifth year follow-up. No drug-related serious adverse events were registered during the study.Conclusions: The present study demonstrated the long-term 24-hour efficacy of travoprost for the treatment of primary open-angle glaucoma.Key Words: open-angle glaucoma, prostaglandin analogue, circadian intraocular pressure, travoprost (J Glaucoma 2014;23:535-540) R eduction of intraocular pressure (IOP) is the only currently available, evidence-based management strategy in patients affected with primary open-angle glaucoma (POAG). Most POAG patients will require lifelong medical therapy to avoid visual loss. The decision to select medical therapy options relies primarily on the efficacy of the available medications in various therapeutic trials. Sadly, most published studies only evaluate the short-term, daytime efficacy of medical therapy.Prostaglandin analogues have become a popular firstline therapy option for lowering IOP in POAG owing to their superior 24-hour efficacy, 1-6 convenient once-a-day administration, 5 and favorable systemic safety profile. 7 Travoprost is a synthetic prostaglandin F2a analogue that exerts its IOP-lowering effect through the prostaglandin FP receptors situated at the ciliary muscle 8 and the trabecular meshwork. 9 Travoprost is increasingly becoming a popular first-line monotherapy option for POAG patients 10 as there is cumulative evidence suggesting good quality of shortterm 24-hour IOP control with low fluctuation, especially with evening administration. 11-13 However, although several controlled studies have demonstrated the daytime short-term efficacy of travoprost monotherapy, [14][15][16] little is currently known about its long-term efficacy.As POA...

show abstract

mentioning

confidence: 99%

Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma

Riva

Katsanos

Floriani

et al. 2014

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…20 Also, increased ocular discomfort is typically associated with long-term use of prostaglandin analogs. 21 A new formulation of bimatoprost with a lower concentration of the drug (0.01%; Lumigan, Allergan, Inc.) has been developed. The goal was to maintain the IOPlowering efficacy achieved with 0.03% formulation while reducing the overall safety profile, particularly in improving ocular surface tolerability.…”

Section: Introductionmentioning

confidence: 99%

Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients

Figus

Nardi

Piaggi

et al. 2014

Eye

View full text Add to dashboard Cite

Results Global clinical score (the sum of pruritus, stinging/burning, blurred vision, sticky eye sensation, eye dryness sensation, and foreign body sensation) significantly decreased in the bimatoprost 0.01% group from baseline 4.7±3.8 to 2.9±2.3 (Po0.001) and 2.5±2.0 (Po0.001) at 6-month and 12-month follow-ups, respectively. Comparison between groups showed differences at both follow-up visits (P ¼ 0.003 and Po0.001, respectively). In vivo confocal microscopy revealed a significant increase in goblet cell density in the bimatoprost 0.01% group compared with the bimatoprost 0.03% group (Po0.001 at both follow-up visits). All functional parameters and conjunctival hyperemia improved in the bimatoprost 0.01% group at each follow-up visit (Po0.05) and in comparison with bimatoprost 0.03% (Po0.05). ConclusionThe results of this trial suggest that bimatoprost 0.01% eye drops seem to decrease the ocular discomfort with respect to bimatoprost 0.03% eye drops.

show abstract

“…Conjunctival hyperemia appears to occur via a secondary mechanism, unrelated to the increased uveoscleral outflow mechanism induced by PGA therapy. While this effect may lessen over time, 48 it may represent a cosmetic concern to the patient, that may lead to poor treatment adherence and thus poor outcomes. 46 In general, PGAs have few systemic adverse events and local ones are mainly transitory or reversible, supporting their use as first line therapy.…”

Section: Dovepressmentioning

confidence: 99%

“…Beta-blockers on the other side have a greater risk of systemic adverse events, but fewer local and cosmetic side-effects. 46,48 Of note, adherence to treatment may depend on side-effects, but also on the frequency of instillation of the drops and the presence of preservative agents, the latter inducing a local reaction, that can have a negative effect on surgery, making the rate of success lower. 49 …”

Section: Dovepressmentioning

confidence: 99%

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

Eyawo

Nachega

Lefèbvre

et al. 2009

OPTH

View full text Add to dashboard Cite

Background: First-line therapy for primary open-angle glaucoma and ocular hypertension generally involves prostaglandin analogue therapy. The relative efficacy of differing prostaglandin therapy is disputed. Methods: A meta-analysis was conducted of head-to-head randomized trials of prostaglandin therapies. We included randomized trials assessing head-to-head evaluations of prostaglandin analogues travoprost, latanoprost and bimatoprost in patients with predominantly primary open-angle glaucoma or ocular hypertension. Findings were interpreted in light of equivalence margins. Results: Our search identified 16 eligible trials, of which 15 were included in the meta-analysis. Trials were, in general, poorly reported. We pooled 9 trials assessing IOP-lowering effects of travoprost vs latanoprost (total n = 1098, weighted mean difference [WMD], -0.24 mmHg, 95% CI, -0.87 to 0.38, P = 0.45, I 2 = 56%, 95% CI, 0 to 0.77, heterogeneity P = 0.01). Eight trials assessed travoprost vs bimatoprost (total n = 714, WMD, 0.88 mmHg, 95% CI, 0.13 to 1.63, P = 0.02, I 2 = 56%, 95% CI, 0% to 78%, heterogeneity P = 0.02). And 8 trials assessed latanoprost vs bimatoprost (total n = 943, WMD, 0.73 mmHg, 95% CI, 0.10 to 1.37, P = 0.02, I 2 = 47%, 95% CI, 0% to 74%, heterogeneity P = 0.06). Travoprost was associated with greater incidence of conjunctival hyperemia than latanoprost (RR 5.71, 95% CI, 1.81 to 18.02, P  0.001, I 2 = 97%, 95% CI, 95 to 98, P  0.001). Five trials assessing latanoprost and bimatoprost revealed an elevated risk of conjunctival hyperemia with bimatoprost (RR 1.59, 95% CI, 1.02 to 2.48, P = 0.04, I 2 = 76%, 95% CI, 16 to 88, P = 0.002). Conclusion: Randomized head-to-head evaluations of prostaglandin therapy demonstrate similar efficacy effects, but differing hyperemia effects.

show abstract

The side effects of the prostaglandin analogues

Cited by 145 publications

References 93 publications

Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma

Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma

Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

Contact Info

Product

Resources

About